title: Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications.
abstract: This trial was designed to test the use of CD34+ selected haemopoietic stem cells (HSC) in HLA-mismatched donor-recipient pairs, following intensive conditioning with thiotepa, antilymphocyte globulin (ALG), cyclophosphamide and single-dose total-body irradiation (sTBI). 10 patients aged 16-50 with advanced malignancies and a two- or three-antigen mismatched family donor entered this study. Donor marrow and G-CSF primed peripheral blood cells were processed separately on CD34 columns (Ceprate). The median number of infused CD34+ cells were 5.66 x 10(6)/ kg, with 0.55 x 10(6)/kg CD3+ cells. Nine patients received cyclosporin for graft-versus-host disease (GvHD) prophylaxis. Median neutrophil counts on day 21 were 2 x 10(9)/l with a median platelet count of 60 x 10(9)/l, but CD4 counts remained extremely depressed throughout the study. Acute GvHD was scored as grade 0-I in two patients, as grade II in seven, and grade III in one. Eight patients died at a median interval of 72 d from HSCT (range 20-144) due to cytomegalovirus (CMV) associated interstitial pneumonitis (IP) (n = 5), renal failure (n = 1). GvHD (n = 1) and Aspergillus meningitis (n = 1). Two patients are alive 365-495 d post transplant, one in remission and one in relapse. This study suggests that large numbers of positively selected mismatched HSC can rapidly engraft after intensive conditioning regimen: however, profound post-transplant immunodeficiency leads to a high risk of lethal infectious complications.
authors.affiliation: Divisione Ematologia II, Ospedale San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: N
authors.initials: N
authors.lastname: Mordini
authors.forename: A
authors.initials: A
authors.lastname: Pitto
authors.forename: G
authors.initials: G
authors.lastname: Piaggio
authors.forename: M
authors.initials: M
authors.lastname: Podestà
authors.forename: F
authors.initials: F
authors.lastname: Benvenuto
authors.forename: M T
authors.initials: MT
authors.lastname: van Lint
authors.forename: M
authors.initials: M
authors.lastname: Valbonesi
authors.forename: G
authors.initials: G
authors.lastname: Lercari
authors.forename: P
authors.initials: P
authors.lastname: Carlier
authors.forename: T
authors.initials: T
authors.lastname: Lamparelli
authors.forename: F
authors.initials: F
authors.lastname: Gualandi
authors.forename: D
authors.initials: D
authors.lastname: Occhini
authors.forename: S
authors.initials: S
authors.lastname: Bregante
authors.forename: O
authors.initials: O
authors.lastname: Figari
authors.forename: M
authors.initials: M
authors.lastname: Soracco
authors.forename: F
authors.initials: F
authors.lastname: Vassallo
authors.forename: G
authors.initials: G
authors.lastname: De Stefano
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34; D016026:Bone Marrow Transplantation / Q000379:methods; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002423:Cause of Death; D003586:Cytomegalovirus Infections / Q000209:etiology; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D018952:Antigens, CD34